Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) Director William Glenn Rice acquired 10,000 shares of Aptose Biosciences stock in a transaction that occurred on Thursday, April 18th. The stock was acquired at an average cost of C$2.44 per share, with a total value of C$24,429.24. Following the completion of the purchase, the director now owns 153,014 shares in the company, valued at approximately C$373,801.57.
William Glenn Rice also recently made the following trade(s):
- On Thursday, March 14th, William Glenn Rice acquired 10,000 shares of Aptose Biosciences stock. The stock was acquired at an average cost of C$2.51 per share, with a total value of C$25,070.76.
Shares of APS stock opened at C$2.55 on Tuesday. Aptose Biosciences Inc. has a fifty-two week low of C$2.08 and a fifty-two week high of C$5.97. The stock has a market capitalization of $101.67 million and a price-to-earnings ratio of -2.95.
Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its earnings results on Tuesday, March 12th. The biotechnology company reported C($0.22) earnings per share for the quarter, missing the consensus estimate of C($0.21) by C($0.01). Sell-side analysts anticipate that Aptose Biosciences Inc. will post -0.8399999904 earnings per share for the current year.
Separately, Royal Bank of Canada reissued an “outperform” rating and issued a C$6.00 price objective on shares of Aptose Biosciences in a research note on Friday, March 1st.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Story: How to interpret a stock’s beta number
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.